What this is
- How it works
- How it works isn't classified yet
- Tested for
- Type 1 Diabetes Mellitus
- Main trialPhase 2
- “INHALE-1st is a Phase 2, single-arm, multi-center, clinical study evaluating the safety and efficacy of Afrezza in combination with subcutaneously-injected basal insulin (BI) for youth 6 to \<18 years old with newly diagnosed stage 3 type 1 diabetes (T1D). The study will also evaluate the effect of an Afrezza plus BI reigmen on participant and parent/legally authorized representative satisfaction. Participants will be followed for 13 weeks during the main phase followed by an optional Extension Phase for participants continuing to use Afrezza in combination with BI for up to 26 weeks.”In the company’s words, NCT07224321 on ClinicalTrials.gov
- Other names
- Technosphere Insulin
Other drugs for Type 1 Diabetes Mellitus
- TirzepatideEli Lilly · Phase 3
- Insulin icodecNovo Nordisk · Phase 3
- CadisegliatinvTv Therapeutics · Phase 3
- Stem Cell Educator therapyYong Zhao, MD, PhD · Phase 3
- VX-017Vertex Pharmaceuticals · Phase 3
- VX-880Vertex Pharmaceuticals · Phase 3
Coming up1
- Mar 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Mar 2027 | INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes | |
| Phase 4Completed | 26 Mar 2024 | INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes | |
| Phase 3Completed | 3 Oct 2024 | Afrezza® INHALE-1 Study in Pediatrics | |
| Phase 2Completed | 17 Mar 2020 | Afrezza Safety and Pharmacokinetics Study in Pediatric Patients |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026